This article is more than 5 years old. Information may no longer be current.
VisiVite launches new macular health supplement
Click Here to Manage Email Alerts
In a press release on Tuesday, VisiVite announced that the company had released AREDS2 Silver, a new macular health vitamin formula with lower zinc levels.
The supplement is based on the National Eye Institute's second Age-Related Eye Disease Study (AREDS2), which found that a lower dose of zinc did not affect efficacy, according to the release. The company is looking to target consumers with zinc allergies and sensitivities with its new formula.
"It is our mission at VisiVite to provide eye health supplements that are constantly evolving and updating to match the latest scientific research," Paul Krawitz, MD, CEO of Vitamin Science Inc. and VisiVite product formulator said in the release. "With our new AREDS2 Silver formula, we are leveraging the newest findings that suggest lower dose zinc works just as well as higher doses. AREDS2 Silver enables zinc-sensitive populations to nourish their eyes with an evidence-backed antioxidant complex that is both well-tolerated and highly effective in promoting macular health."
The AREDS2 Silver formula contains 40 mg zinc, 10 mg FloraGlo lutein, 2 mg OmniXan zeaxanthin as well as 500 mg vitamin C and 400 IU vitamin E.